Moderna CEO warns China is investing heavily in mRNA as Beijing challenges US in biotechnology

Moderna's 177% stock surge followed its mRNA cancer vaccine success, but CEO Stéphane Bancel says China's biotechnology ...
24/7 Wall St.

Moderna Sinks 7% as Traders Book Profits on a 392% Year-to-Date Surge; BioNTech Drops 4%, Merck Slips

Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is down 7% to $135.22 in Monday morning trading, cooling off after one of ...
Blockonomi

Moderna (MRNA) Stock Skyrockets 177% on Melanoma Vaccine Breakthrough – Can It Last?

Moderna (MRNA) stock exploded 177% on melanoma vaccine trial success, marking the biggest S&P 500 gain in 20+ years. Analysts ...

Moderna and Merck’s cancer vaccine clears phase 3; Ultragenyx lands gene therapy nod

A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower ...

Moderna stock slides Monday following historic rally: What's going on?

Shares of Moderna Inc. MRNA are trading lower Monday morning, taking a breather following a multi-day surge driven by ...

Moderna Shares Skyrocket 125% Toward Best Day Ever—On Success Of Cancer Drug Trial

Shares of Moderna rocketed by 93% to around $121.90 on Wednesday, pacing what would be the stock’s best-ever trading session ...

Notable healthcare headlines for the week: Moderna, Merck, and Twist Bioscience in focus

Wall Street’s major averages closed firmly higher on Friday, with Treasury yields largely steady and Bitcoin experiencing sharp intraday swings. The Dow Jones Industrial Average advanced 0.9%, the S&P ...

Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped

Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.